Drug intelligence / Profile preview

JMEY-TM91

Development stage: Unknown
Lead developer: Jianmin Pharmaceutical Group
Modality: Small Molecules

Overview

JMEY-TM91 is a pediatric drug candidate under development by Jianmin Pharmaceutical Group for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). Developed through the Jianmin Pediatric Research Institute, the agent is currently in Phase 1 clinical trials. As of the current pipeline disclosures, specific details regarding its pharmacological target, molecular structure, or modality have not been released, although it is categorized within the company's pediatric clinical-stage portfolio.

Beyond the preview

Go deeper on JMEY-TM91.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JMEY-TM91.

Explore the full profile